The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.
Age 18-75 years, gender not specified;
Pathologically or clinically confirmed colorectal cancer liver metastases, with liver lesions unsuitable for surgical resection or intolerance or refusal of surgical resection;
In the case of an unresectable primary tumor or recurrence, the absence of serious complications such as bleeding or obstruction;
Failure of first-line treatment, with disease progression or new liver metastases;
Liver function Child-Pugh class C;
Expected survival < 3 months;
Major organ insufficiency or failure;
Active infection;